RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

The best arguments against ADHD would be
1) CX717 isn't viable for chronic use, and CX1739 has no POC
2) the psychostimulants are sufficiently dominant that a nonstimulant will not reach sufficient sales magnitude, particularly with Strattera--and we don't actually know how CX1739 would fare against it--still controlling the nonstim sector.

Against RD:
1) The IV form of CX717 hasn't been tested in humans
2) CX1739 has no POC in RD.

Overall:
For some people, Cortex has already been defined by the clinical hold, and they aren't taking in new information.

Addendum--also, one could respond with 'we have 150 other partnership proposals on the docket, and until we look at them all, we can't be sure this is the best route to go...'

NeuroInvestment